首页> 外文会议>Annual meeting exposition of the Controlled Release Society >Folate Receptor-Targeted Supramolecular Vesicular Aggregates (SVAs) for Anticancer Therapy
【24h】

Folate Receptor-Targeted Supramolecular Vesicular Aggregates (SVAs) for Anticancer Therapy

机译:叶酸受体靶向的超分子囊泡(SVA)的抗癌治疗。

获取原文

摘要

Suparmolecular vesicular aggregates (SVAs) wereachieved by self-assembling of an ,on-poly(aspartylhydrazide) copolymer bearing both folatemoieties and lipid anchors with Dipalmitoylphosphatidyl-choline and cholesterol, thus forming avesicular structure with the polymeric chains on thesurface. The physicochemical and pharmaceuticalparameters of SAVs were investigated. Gemcitabine wasused as a drug model. The in vitro anticancer activity ofSVAs was evaluated against breast cancer cells (MCF-7and BxPC-3 cell lines). Confocal laser scanningmicrosopy and flow cytometric analysis, as well as invitro binding experiments, were carried out to evaluatethe folate targeting features and the intracellular druguptake. Pharmacokinetic and biodistribution experimentswere also carried out.
机译:超分子水泡聚集体(SVA)是 通过自行组装 均含有叶酸的聚(天冬氨酰肼)共聚物 半棕榈酰基磷脂酰- 胆碱和胆固醇,从而形成 囊状结构,聚合物链在 表面。理化和制药 对SAV的参数进行了研究。吉西他滨原为 用作药物模型。紫杉醇的体外抗癌活性 评估了SVA对乳腺癌细胞(MCF-7 和BxPC-3细胞系)。共聚焦激光扫描 微粒和流式细胞仪分析,以及 进行体外结合实验以评估 叶酸靶向特征和细胞内药物 摄取。药代动力学和生物分布实验 也进行了。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号